Hemocompatibility and Long‐Term Outcomes in H eart W are Versus H eart M ate II Versus H eart M ate 3: Multicenter Real‐World Cohort
Artificial Organs · 2026-04 · 50 (4) · 580-589
DOI: 10.1111/aor.70086 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Artificial Organs, online erschienen am 04.01.2026. Verfasst von Hamza H H Ben Nasir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Operative Intensive Care, Klinikum Links der Weser gGmbH, Bremen, Germany. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
To compare overall and hemocompatibility‐related outcomes across third‐generation centrifugal‐flow HeartMate 3 (HM3) versus second‐generation axial‐flow HeartMate II (HMII) and centrifugal‐flow HeartWare (HVAD) in routine clinical practice.
Methods
We conducted a multicenter observational cohort of adult LVAD recipients ( n = 327: HVAD n = 112, HMII n = 142, HM3 n = 73). Baseline characteristics and perioperative variables were recorded. Overall survival was analyzed using Kaplan–Meier and Cox proportional hazards models with HM3 as reference. Hemocompatibility‐related adverse events (HRAE; pump thrombosis, ischemic stroke, major bleeding) were assessed with cumulative incidence functions (Aalen–Johansen) and Fine–Gray competing‐risk regression with death as a competing event; the hemocompatibility score (HCS) summarized event burden over follow‐up.
Results
HM3 demonstrated superior long‐term survival compared with both HMII and HVAD in Kaplan–Meier analyses (log‐rank p < 0.001); this advantage persisted in multivariable Cox models. HRAE‐free survival was also higher with HM3 on competing‐risk analysis, driven by substantially lower pump thrombosis and fewer ischemic strokes relative to HMII and HVAD. Bleeding burden did not differ materially between devices, consistent with a class effect of continuous‐flow support. LDH‐based hemolysis markers and HCS distributions further favored HM3. Perioperative course and general postoperative complications were otherwise broadly comparable across devices.
Conclusions
In this real‐world, multicenter cohort, HM3 was associated with better overall survival and a lower thromboembolic burden than HMII and HVAD, while bleeding risk remained similar. These findings support preferential selection of HM3 when device choice is feasible, and emphasize the need for targeted strategies to mitigate hemostatic complications across all LVADs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology and Operative Intensive Care, Klinikum Links der Weser gGmbH, Bremen, Germany.
- Department of Cardiac Surgery, RWTH University Hospital, Aachen, Germany.
- Department of Cardiothoracic Surgery, Faculty of Medicine, Qena University, Qena, Egypt.
- Department of Cardiac Surgery, Heart Centre Dresden, Technische Universität Dresden, Dresden, Germany.
- Department of Cardiothoracic Surgery, Heart Centre Trier, Barmherzigen Brueder Hospital, Trier, Germany.
- Department of Cardiac Surgery, University Hospital Schleswig-Holstein, Kiel, Germany.
ORCID-Profile: Hamza H H Ben Nasir, Alish Kolashov, Yusuf Shieba, Bernd Panholzer, Ajay Moza, Rashad Zayat
Zitieren
APA
Ben Nasir, H. H. H., Mohammed, A. F. A., Allham, O., Kolashov, A., Shieba, Y., Tewarie, L., Panholzer, B., Moza, A., Haneya, A., & Zayat, R. (2026). Hemocompatibility and Long‐Term Outcomes in H eart W are Versus H eart M ate II Versus H eart M ate 3: Multicenter Real‐World Cohort. Artificial Organs, 50(4), 580-589. https://doi.org/10.1111/aor.70086
Vancouver
Ben Nasir HHH, Mohammed AFA, Allham O, Kolashov A, Shieba Y, Tewarie L, et al. Hemocompatibility and Long‐Term Outcomes in H eart W are Versus H eart M ate II Versus H eart M ate 3: Multicenter Real‐World Cohort. Artificial Organs. 2026;50(4):580-589. doi:10.1111/aor.70086
BibTeX
@article{BenNasir2026,
author = {Ben Nasir, Hamza H H and Mohammed, Ahmed F A and Allham, Omar and Kolashov, Alish and Shieba, Yusuf and Tewarie, Lachmandath and Panholzer, Bernd and Moza, Ajay and Haneya, Assad and Zayat, Rashad},
title = {Hemocompatibility and Long‐Term Outcomes in H eart W are Versus H eart M ate II Versus H eart M ate 3: Multicenter Real‐World Cohort},
journal = {Artificial Organs},
year = {2026},
volume = {50},
number = {4},
pages = {580--589},
doi = {10.1111/aor.70086}
}
EUVIMED